Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016

Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global Dermatophytic Onychomycosis Therapeutics market to grow at a CAGR of 7.28 percent over the period 2012-2016. One of the key factors contributing to this market growth is the strong and promising pipeline. The Global Dermatophytic Onychomycosis Therapeutics market has also been witnessing an increased focus on combination therapies for the treatment of dermatophytic onychomycosis. However, the adverse side effects associated with drugs could pose a challenge to the growth of this market. 
TechNavio's report, Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Dermatophytic Onychomycosis Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
The key vendors dominating this market space are Anacor Pharmaceuticals Inc., Celtic Pharmaceutical Holdings L.P., Genelabs Technologies Inc., Hisamitsu Pharmaceutical Co. Inc., Janssen Biotech Inc., Mayne Pharma Ltd., Merck & Co. Inc., NanoBio Corp., Novartis International AG, Palau Pharma S.A., Pfizer Inc., Promius Pharma LLC , Stiefel laboratories Inc., Topica Pharmaceuticals Inc., Valeant Pharmaceuticals International 
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

 

 

01. Executive Summary

02. Scope of the Report


02.1 Market Overview

02.2 Product Offerings

03. Market Research Methodology

03.1 Market Research Process

03.2 Research Design

03.3 Research Methodology

04. List of Abbreviations

05. Introduction

06. Types of Dermatophytic Onychomycosis


06.1.1 Distal Subungual Onychomycosis

06.1.2 Proximal Subungual Onychomycosis

06.1.3 White Superficial Onychomycosis

06.1.4 Candidal Onychomycosis

07. Currently Approved Drugs

07.1 Oral Agents

07.1.1 Terbinafine

07.1.2 Itraconazole

07.1.3 Griseofulvin

07.1.4 Fluconazole

07.2 Topical Agents

07.2.1 Ciclopirox

07.2.2 Amorolfine

07.2.3 Ketoconazole

08. Market Landscape

08.1 Market Overview

08.2 Market Size and Forecast

08.3 Dermatophytic Onychomycosis Market in the US

08.3.1 Market Segmentation

08.3.2 Itraconazole Sales in the US

08.3.3 Flucanozole Sales in the US

08.3.4 Griseofulvin Sales in the US

08.3.5 Ketoconazole Sales in the US

08.4 Five Forces Analysis

09. Geographical Segmentation

09.1 Global Dermatophytic Onychomycosis Therapeutics Market by Geographical Segmentation 2012-2016

10. Rate of Incidence and Prevalence

11. Pipeline Analysis

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape


19.1 Competitive Scenario

19.1.1 Key News

19.1.2 Mergers and Acquisitions

19.2 Other Prominent Vendors

20. Key Vendor Analysis

20.1 Anacor Pharmaceuticals Inc.

20.1.1 Business Overview

20.1.2 Key Information

20.1.3 SWOT Analysis

20.2 Janssen Biotech Inc.

20.2.1 Business Overview

20.2.2 Key Information

20.2.3 SWOT Analysis

20.3 Novartis International AG

20.3.1 Business Overview

20.3.2 Business Segmentation

20.3.3 Key Information

20.3.4 SWOT Analysis

20.4 Pfizer Inc.

20.4.1 Business Overview

20.4.2 Business Segmentation

20.4.3 Key Information

20.4.4 SWOT Analysis

21. Other Reports in this Series



List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Nail Unit Dorsal and Lateral View

Exhibit 3: Types of Dermatophytic Onychomycosis

Exhibit 4: Global Dermatophytic Onychomycosis Therapeutics Market Overview

Exhibit 5: Global Dermatophytic Onychomycosis Therapeutics Market 2012-2016 (US$ billion)

Exhibit 6: Dermatophytic Onychomycosis Therapeutics Market in the US 2012-2016 (US$ million)

Exhibit 7: Dermatophytic Onychomycosis Market in the US Segmentation

Exhibit 8: Itraconazole Sales in the US 2012-2016 (US$ million)

Exhibit 9: Fluconazole Sales in the US 2012-2016 (US$ million)

Exhibit 10: Griseofulvin Sales in the US 2012-2016 (US$ million)

Exhibit 11: Ketoconazole Sales in the US 2012-2016 (US$ million)

Exhibit 12: Global Dermatophytic Onychomycosis Therapeutics Market by Geographical Segmentation 2012

Exhibit 13: Business Segmentation of Novartis International AG

Exhibit 14: Business Segmentation of Pfizer Inc.



 


Enquiry Before Buy
image
Can´t read the image ? refresh here.